Publicité
Biotech Finances - L'information stratégique des biodécideurs et des bioinvestisseurs
SEARCH THE SITE
AND ARCHIVES
May 17th, 2012
 Remember me 
 

NEW

Would you like to have your say on the Eco notes by H. Ella?
Share your comments with us by going to Eco Note.

 
 

BREAKING NEWS

NICOX: IT’S OVER FOR NAPROXCINOD

Dr Michele Garufi’s team wanted to believe in it until the bitter end, but this time NicOx has reached the point of no return with its lead compound naproxcinod…

More...

 

LOOK INSIDE

Lettre 445

EXCLUSIVE

All transactions in Europe and Israel of the last six months and previews of the next half year by analysts all over Europe.

More...

 
 

INTERVIEW

PHARMAS PUT THE HUMAN BACK AT THE CENTRE OF THEIR STRATEGIES

Priscilla Motte

Priscilla Motte, dans le n°504 du 25/04/2011

In recent years, the leadership model has been primarily based on performance and goals, but is this compatible with the current economic crisis? Should we review our management style? When the market shrinks and customers are difficult, isn’t there another form of employee motivation and a different style of leadership that would be more appropriate? Priscilla Motte, Partner in charge of &q...

More...

 
 

Recommendations

"For me, Biotech Finances is a unique source of information about the important participants and their strategies in biotech. Biotech Finances has the merit of being able to make a sometimes complex reality understandable in clear and simple words."

Stéphane Olmi , Manager, LAZARD FRERES

"In a sector where information seems to abound, every week Biotech Finances offers a selective, alert and sharp view on the strategy of European pharmaceutical companies and their economic environment. This double treatment, both scientific and business, of the news in life sciences is rare and makes this publication stand out. It is also an excellent decoding tool for professionals."

Bruno Arabian, CEO, MILESTONE

"I appreciate Biotech Finances because it offers both quick information and analysis."

Dr Gilles Avenard, CEO, BIOALLIANCE PHARMA 

"Biotech Finances is the only specialized support system in France that gives in-depth information about the medical equipment sector, which is a sector in full development. This is why, for me, it is the best source of information about medtech."

Ismaël Nujurally, CEO, THERACLION

"Biotech Finances is created with an entrepreneurial spirit and brings together the views of different players in biotechnology financing. In addition to being a comprehensive source of information, it sheds light on what's going on in the background of the sector in Europe."

Jean-Yves Nothias, General Partner, BioConvergence Team, SOCIETE GENERALE ASSET MANAGEMENT

Biotech Finances brings us every week the most important information about financial activity and transactions in the biotech sector in Europe. As capital investors we're able to find what we need in less than 10 minutes of reading per week. Bravo!"

Isabelle de Crémoux, General  Partner, Director of Lifesciences Department, SEVENTURE

"I never miss an issue of Biotech Finances. It's an excellent vehicle for all the essential information about activity in the sector."

Frédéric Desdouits, Managing Partner at BIONEST- Healthcare Strategic Consulting and M&A.

"For me, Biotech Finances is a unique source of information about the important participants and their strategies in biotech. Biotech Finances has the merit of being able to make a sometimes complex reality understandable in clear and simple words."

Stéphane Olmi , Manager, LAZARD FRERES

Read all Recommendations

 
 
 

Eco Note of the week, as seen by ...

\"Eco
 

Press Releases

 
 
Partenaires
 
 
 
Pub